"Breaking through other technological barriers?"
Upon hearing Xu Yun's words, Tian Liangwei's expression hardly changed, but Zheng Zu was slightly taken aback:
Good heavens.
Does this kid really think that breaking through technological barriers like Imidacloprid is that easy?
One must understand.
Even for the fund's various leaders, the company's functional positioning is just a professional biological pesticide manufacturing enterprise.
However, even this so-called 'just' represents an incredibly vast market!
Though Zheng Zu inwardly belittled Xu Yun for overestimating himself, he managed his facial expression well and provided a highly professional solution:
"This issue is actually quite straightforward, Dr. Xu. If the patent lists you as the first inventor, then you can choose to draw an additional licensing fee after obtaining the current dividends.
For example, draw 3% or 5% of the sales profit; many companies like Google and Microsoft operate this way.
